Yusuke Nakamura to Deoxycytidine
This is a "connection" page, showing publications Yusuke Nakamura has written about Deoxycytidine.
Connection Strength
0.540
-
Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 2017 Jan; 108(1):73-80.
Score: 0.134
-
A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy. Pharmacogenet Genomics. 2012 Apr; 22(4):229-35.
Score: 0.096
-
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res. 2012 Jan 15; 18(2):577-84.
Score: 0.094
-
Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 2010 Feb; 101(2):433-9.
Score: 0.081
-
[A phase I study of combination-therapy with gemcitabine and epitope peptides derived from human vascular endothelial growth factor receptor for unresectable or recurrent pancreas cancer]. Gan To Kagaku Ryoho. 2008 Nov; 35(12):2271-3.
Score: 0.076
-
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation. PLoS One. 2018; 13(8):e0202272.
Score: 0.037
-
Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer. Pancreas. 2009 Oct; 38(7):791-8.
Score: 0.020